JP2013518107A5 - - Google Patents

Download PDF

Info

Publication number
JP2013518107A5
JP2013518107A5 JP2012551213A JP2012551213A JP2013518107A5 JP 2013518107 A5 JP2013518107 A5 JP 2013518107A5 JP 2012551213 A JP2012551213 A JP 2012551213A JP 2012551213 A JP2012551213 A JP 2012551213A JP 2013518107 A5 JP2013518107 A5 JP 2013518107A5
Authority
JP
Japan
Prior art keywords
acceptable salt
pharmaceutically acceptable
combination
abacavir
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012551213A
Other languages
English (en)
Other versions
JP2013518107A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/022219 external-priority patent/WO2011094150A1/en
Publication of JP2013518107A publication Critical patent/JP2013518107A/ja
Publication of JP2013518107A5 publication Critical patent/JP2013518107A5/ja
Pending legal-status Critical Current

Links

Claims (11)

  1. 式（Ｉ）の化合物：
    Figure 2013518107

    またはその薬学上許容される塩と、アバカビルまたはその薬学上許容される塩と、ラミブジンまたはその薬学上許容される塩とを含んでなる、組み合わせ。
  2. 式（Ｉ）の化合物の薬学上許容される塩が、ナトリウム塩である、請求項１に記載の組み合わせ。
  3. アバカビルの薬学上許容される塩がヘミ硫酸塩である、請求項１または２に記載の組み合わせ。
  4. ＨＩＶ感染治療用の請求項１〜３のいずれかに記載の組み合わせ。
  5. 請求項１〜３のいずれかに記載の組合せを、薬学上許容される担体とともに含んでなる、医薬組成物。
  6. さらにエファビレンツを含む、請求項５に記載の医薬組成物。
  7. 式（Ｉ）の化合物の薬学上許容される塩が、ナトリウム塩である、請求項５または６に記載の医薬組成物。
  8. アバカビルの薬学上許容される塩がヘミ硫酸塩である、請求項５または６に記載の医薬組成物。
  9. 前記組み合わせが、同時に投与される、請求項１〜４のいずれかに記載の組み合わせ。
  10. 前記組み合わせが、連続的に投与される、請求項１〜４のいずれかに記載の組み合わせ。
  11. 請求項１に記載の式（Ｉ）の化合物またはその薬学上許容される塩と、アバカビルまたはその薬学上許容される塩と、ラミブジンまたはその薬学上許容される塩とを含んでなる、患者用パック。
JP2012551213A 2010-01-27 2011-01-24 抗ウイルス療法 Pending JP2013518107A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29858910P 2010-01-27 2010-01-27
US61/298,589 2010-01-27
PCT/US2011/022219 WO2011094150A1 (en) 2010-01-27 2011-01-24 Antiviral therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016015242A Division JP2016145204A (ja) 2010-01-27 2016-01-29 抗ウイルス療法

Publications (2)

Publication Number Publication Date
JP2013518107A JP2013518107A (ja) 2013-05-20
JP2013518107A5 true JP2013518107A5 (ja) 2014-03-13

Family

ID=44319704

Family Applications (8)

Application Number Title Priority Date Filing Date
JP2012551213A Pending JP2013518107A (ja) 2010-01-27 2011-01-24 抗ウイルス療法
JP2016015242A Pending JP2016145204A (ja) 2010-01-27 2016-01-29 抗ウイルス療法
JP2016161610A Active JP6268386B2 (ja) 2010-01-27 2016-08-22 抗ウイルス療法
JP2018072861A Pending JP2018127473A (ja) 2010-01-27 2018-04-05 抗ウイルス療法
JP2019106635A Pending JP2019167371A (ja) 2010-01-27 2019-06-07 抗ウイルス療法
JP2021030306A Pending JP2021091705A (ja) 2010-01-27 2021-02-26 抗ウイルス療法
JP2022032464A Pending JP2022071126A (ja) 2010-01-27 2022-03-03 抗ウイルス療法
JP2023060638A Pending JP2023085431A (ja) 2010-01-27 2023-04-04 抗ウイルス療法

Family Applications After (7)

Application Number Title Priority Date Filing Date
JP2016015242A Pending JP2016145204A (ja) 2010-01-27 2016-01-29 抗ウイルス療法
JP2016161610A Active JP6268386B2 (ja) 2010-01-27 2016-08-22 抗ウイルス療法
JP2018072861A Pending JP2018127473A (ja) 2010-01-27 2018-04-05 抗ウイルス療法
JP2019106635A Pending JP2019167371A (ja) 2010-01-27 2019-06-07 抗ウイルス療法
JP2021030306A Pending JP2021091705A (ja) 2010-01-27 2021-02-26 抗ウイルス療法
JP2022032464A Pending JP2022071126A (ja) 2010-01-27 2022-03-03 抗ウイルス療法
JP2023060638A Pending JP2023085431A (ja) 2010-01-27 2023-04-04 抗ウイルス療法

Country Status (45)

Country Link
US (12) US20120295898A1 (ja)
EP (6) EP3127542B1 (ja)
JP (8) JP2013518107A (ja)
KR (4) KR20170078868A (ja)
CN (2) CN105311033B (ja)
AP (1) AP3551A (ja)
AU (1) AU2011209788C1 (ja)
BR (1) BR112012018670A2 (ja)
CA (4) CA2787691C (ja)
CL (1) CL2012002080A1 (ja)
CO (1) CO6602152A2 (ja)
CR (1) CR20120423A (ja)
CY (4) CY1116509T1 (ja)
DK (4) DK3494972T3 (ja)
DO (2) DOP2012000205A (ja)
EA (4) EA025176B1 (ja)
EC (1) ECSP12012106A (ja)
ES (3) ES2670811T3 (ja)
FI (1) FI3494972T3 (ja)
FR (1) FR18C1043I2 (ja)
HK (3) HK1209629A1 (ja)
HR (4) HRP20240168T1 (ja)
HU (4) HUE026849T2 (ja)
IL (5) IL221007A (ja)
LT (4) LT2932970T (ja)
LU (1) LUC00090I2 (ja)
MA (1) MA34002B1 (ja)
ME (2) ME03058B (ja)
MX (4) MX367937B (ja)
MY (1) MY188334A (ja)
NO (2) NO2932970T3 (ja)
NZ (4) NZ627827A (ja)
PE (2) PE20121524A1 (ja)
PH (2) PH12016500195A1 (ja)
PL (3) PL3127542T3 (ja)
PT (4) PT2932970T (ja)
RS (4) RS57728B1 (ja)
SG (3) SG10201707183TA (ja)
SI (4) SI3127542T1 (ja)
SM (1) SMT201500177B (ja)
TN (1) TN2012000376A1 (ja)
TR (1) TR201807704T4 (ja)
UA (1) UA105556C2 (ja)
WO (1) WO2011094150A1 (ja)
ZA (1) ZA201205586B (ja)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA025176B1 (ru) 2010-01-27 2016-11-30 Вайв Хелткер Компани Комбинация для лечения вич-инфекции
JP2015534973A (ja) 2012-10-23 2015-12-07 シプラ・リミテッド 抗レトロウイルス医薬組成物
MY191741A (en) 2012-12-21 2022-07-13 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP2956123A1 (en) * 2013-02-18 2015-12-23 ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
EP2767272A1 (en) * 2013-02-18 2014-08-20 Ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
NO2865735T3 (ja) 2013-07-12 2018-07-21
HUE037347T2 (hu) 2013-07-12 2018-08-28 Gilead Sciences Inc Policiklusos karmaboilpiridon vegyületek és alkalmazásuk HIV fertõzések kezelésére
AP2016009157A0 (en) 2013-09-27 2016-04-30 Merck Sharp & Dohme Substituted quinolizine derivatives useful as hiv integrase inhibitors
WO2015140569A1 (en) 2014-03-20 2015-09-24 Cipla Limited Pharmaceutical composition
EP3151920A4 (en) 2014-06-04 2017-12-27 Sanford-Burnham Medical Research Institute Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
NO2717902T3 (ja) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
CN107074875B (zh) 2014-07-29 2019-03-29 斯洛文尼亚莱柯制药股份有限公司 度鲁特韦钠的新水合物
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
PL3277691T3 (pl) 2015-04-02 2019-07-31 Gilead Sciences, Inc. Policykliczne związki karbamoilopirydonowe i ich zastosowanie farmaceutyczne
EP3334419A1 (en) 2015-08-14 2018-06-20 Sandoz AG Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2017205585A1 (en) * 2016-05-27 2017-11-30 Viiv Healthcare Company Combinations and uses treatments thereof
WO2018028841A1 (en) * 2016-08-12 2018-02-15 Sandoz Ag Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2018042332A1 (en) * 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
US20200147092A1 (en) * 2017-07-21 2020-05-14 Viiv Healthcare Company Regimens for treating hiv infections and aids
CN117298114A (zh) 2017-07-21 2023-12-29 Viiv保健公司 用于治疗hib感染和aids的方案
US20200230141A1 (en) * 2017-10-13 2020-07-23 Viiv Healthcare Company Bi-layer pharmaceutical tablet formulation
UA127822C2 (uk) 2019-03-22 2024-01-10 Гіліад Сайєнсіз, Інк. Місткові трициклічні карбамоїлпіридонові сполуки та їх фармацевтичне застосування
WO2021142150A1 (en) * 2020-01-09 2021-07-15 University Of Washington Long-acting therapeutic agent combinations and methods thereof
US11697652B2 (en) 2020-02-24 2023-07-11 Gilead Sciences, Inc. Tetracyclic compounds and uses thereof
SI4196479T1 (sl) 2021-01-19 2024-01-31 Gilead Sciences, Inc. Substituirane piridotriazinske spojine in njihove uporabe
WO2023164293A1 (en) * 2022-02-28 2023-08-31 Jericho Sciences, Llc Methods for viral infections

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
IL106507A (en) 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
US5665720A (en) 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
GB9402161D0 (en) 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
UA49803C2 (uk) 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
KR20000022226A (ko) * 1996-06-25 2000-04-25 그레이엄 브레레톤;레슬리 에드워즈 Hiv 치료에 사용하기 위한 vx478, 지도부딘, ftc 및(또는) 3tc를 포함하는 배합물
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
GB9709945D0 (en) 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
GB9717928D0 (en) 1997-08-22 1997-10-29 Glaxo Group Ltd Process for the enatioselective hydrolysis of n-derivatised lactams
GB9721780D0 (en) 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6087383A (en) 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
GB9805898D0 (en) 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
AU3366899A (en) 1998-03-27 1999-10-18 Regents Of The University Of California, The Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
CA2661804C (en) 2000-01-31 2014-04-01 Cook Biotech Incorporated Stent valves and uses of same
BRPI0208811B8 (pt) 2001-04-10 2021-05-25 Pfizer derivados de pirazol, seu uso e processo de preparação, bem como composição farmacêutica compreendendo os mesmos
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
TW200403061A (en) * 2002-06-04 2004-03-01 Glaxo Group Ltd Pharmaceutical compositions
PL373758A1 (en) 2002-06-27 2005-09-05 Medivir Ab Synergistic interaction of abacavir and alovudine
ES2308136T3 (es) * 2003-01-14 2008-12-01 Gilead Sciences, Inc. Composiciones y procedimientos para la politerapia antiviral.
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
US8691991B2 (en) * 2004-02-11 2014-04-08 Shionogi & Co., Ltd. 2-oxonaphthyridine-3-carboxamides HIV integrase inhibitors
CA2562713A1 (en) * 2004-04-14 2005-12-15 Gilead Sciences, Inc. Phosphonate analogs of hiv integrase inhibitor compounds
EP1758581A1 (en) * 2004-05-21 2007-03-07 Japan Tobacco, Inc. Combinations comprising a 4-isoquinolone derivative and anti-hiv agents
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
DE202005021414U1 (de) 2004-08-23 2008-03-20 Teva Pharmaceutical Industries Ltd. Festes und kristallines Ibandronat-Natrium
KR101284361B1 (ko) 2004-09-02 2013-07-15 얀센 파마슈티카 엔.브이. 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드
WO2006054182A2 (en) 2004-09-16 2006-05-26 Idenix Pharmaceuticals, Inc. Phosphoindoles as hiv inhibitors
WO2006096444A2 (en) 2005-03-04 2006-09-14 Smithkline Beecham Corporation Chemical compounds
EA014162B1 (ru) * 2005-04-28 2010-10-29 Смитклайн Бичем Корпорейшн Полициклическое карбамоилпиридоновое производное, обладающее ингибиторной активностью в отношении интегразы вич
UA96568C2 (en) * 2005-04-28 2011-11-25 Глаксосмиткляйн Ллк Polycyclic carbamoyl pyridone derivative as hiv-integrase inhibitor
KR20140082858A (ko) 2005-12-30 2014-07-02 길리애드 사이언시즈, 인코포레이티드 Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법
UA101141C2 (ru) * 2005-12-30 2013-03-11 Гилиад Сайенсиз, Инк. Способ улучшения фармакокинетики ингибиторов интегразы вич
ME01617B (me) * 2006-01-20 2014-09-20 Janssen R&D Ireland Dugotrajno tretiranje hiv-infekcije s tcm278
US20080039428A1 (en) 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
NZ573887A (en) 2006-07-21 2012-02-24 Gilead Sciences Inc Antiviral protease inhibitors
MX2009003410A (es) 2006-09-29 2009-07-17 Idenix Pharmaceuticals Inc Fosfoindoles enantiomericamente puros como inhibidores de vih.
BRPI0807581A2 (pt) 2007-02-23 2014-07-01 Gilead Science Inc Moduladores de propriedades farmacocinéticas de produtos terapêuticos
TW200835693A (en) 2007-02-23 2008-09-01 Auspex Pharmaceuticals Inc Preparation and utility of non-nucleoside reverse transcriptase inhibitors
KR20100041798A (ko) 2007-06-29 2010-04-22 한국화학연구원 신규 ｈｉｖ 역전사효소 억제제
EP2167476B1 (en) 2007-06-29 2015-02-25 Korea Research Institute Of Chemical Technology Novel hiv reverse transcriptase inhibitors
AR067412A1 (es) 2007-07-06 2009-10-07 Gilead Sciences Inc Moduladores de propiedades farmaceuticas de productos terapeuticos
WO2009007441A2 (en) 2007-07-12 2009-01-15 Tibotec Pharmaceuticals Ltd. Crystalline form of (e) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile
WO2009058923A1 (en) 2007-10-31 2009-05-07 Smithkline Beecham Corporation Ccr5 antagonists as therapeutic agents
WO2009059243A1 (en) 2007-11-01 2009-05-07 The Uab Research Foundation Treating and preventing viral infections
US8108055B2 (en) 2007-12-28 2012-01-31 Larry Wong Method, system and apparatus for controlling an electrical device
CA2711424A1 (en) * 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel lupane derivatives
EP2240504A1 (en) 2008-01-03 2010-10-20 Virochem Pharma Inc. Novel c-21-keto lupane derivatives preparation and use thereof
US8759379B2 (en) 2008-01-04 2014-06-24 Gilead Sciences, Inc. Inhibitors of cytochrome P450
WO2009100532A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. NOVEL 17ß LUPANE DERIVATIVES
WO2009148600A2 (en) * 2008-06-06 2009-12-10 Concert Pharmaceuticals, Inc. Deuterated lysine-based compounds
SI2320908T1 (sl) * 2008-07-25 2014-05-30 Viiv Healthcare Company Predzdravila dolutegravirja
PT2376453T (pt) * 2008-12-11 2020-01-14 Shionogi & Co Processos e intermediários para inibidores carbamoilpiridona da integrase de vih
CA2744019C (en) 2008-12-11 2017-03-14 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
EA025176B1 (ru) 2010-01-27 2016-11-30 Вайв Хелткер Компани Комбинация для лечения вич-инфекции
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
US8933075B2 (en) 2010-06-17 2015-01-13 Fuzians Biomedicals, Inc. Compounds useful as antiviral agents, compositions, and methods of use

Similar Documents

Publication Publication Date Title
JP2013518107A5 (ja)
JP2012255026A5 (ja)
JP2013542247A5 (ja)
JP2013032389A5 (ja)
JP2013509429A5 (ja)
JP2017537066A5 (ja)
JP2009535352A5 (ja)
JP2013508279A5 (ja)
JP2015078230A5 (ja)
JP2012502037A5 (ja)
JP2008533007A5 (ja)
HRP20150770T1 (hr) Terapijska kombinacija koja sadrži dolutegravir, abakavir i lamivudin
JP2010077141A5 (ja)
JP2016508134A5 (ja)
JP2016515561A5 (ja)
JP2015024998A5 (ja)
JP2013507439A5 (ja)
JP2011102304A5 (ja)
JP2013525444A5 (ja)
JP2007302689A5 (ja)
JP2013014622A5 (ja)
JP2014500861A5 (ja)
JP2012532874A5 (ja)
IL295418B1 (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
JP2009545527A5 (ja)